Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: $FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 4D Molecular Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 4D Molecular Therapeutics's position in the market.
4DMT reported positive interim data from the PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, advancing into Phase 3 by Q1 2025. They presented 24-week analysis from the Population Extension cohort and Phase 1/2 AEROW trial at upcoming conferences. Additionally, they completed a public follow-on offering raising $337 million, ensuring cash runway into H1 2027.
4D Molecular Therapeutics, a leading genetic medicines company, will participate in an investor conference in May. The management team will conduct a fireside chat and be available for one-on-one meetings. The presentation will take place on May 14, 2024, at the Bank of America Health Care Conference.
4DMT, a genetic medicines company, announced presentations at the 2024 ARVO Annual Meeting, including interim results from the PRISM Phase 2 trial for 4D-150 and preclinical data on 4D-175. The Company aims to treat diseases like AMD through genetic medicine.